Conditions:  Advanced Clear Cell Renal Cell Carcinoma;  Advanced Papillary Renal Cell Carcinoma;  Advanced Renal Cell Carcinoma;  Advanced Sarcomatoid Renal Cell Carcinoma;  Metastatic Clear Cell Renal Cell Carcinoma;  Metastatic Papillary Renal Cell Carcinoma;  Metastatic Renal Cell Carcinoma;  Metastatic Sarcomatoid Renal Cell Carcinoma;  Stage III Renal Cell Cancer AJCC v8;  Stage IV Renal Cell Cancer AJCC v8;  Unresectable Clear Cell Renal Cell Carcinoma;  Unresectable Renal Cell Carcinoma
Interventions:  Drug: Cabozantinib S-malate;  Drug: Clostridium butyricum CBM 588 Probiotic Strain;  Biological: Nivolumab
Sponsors:  City of Hope Medical Center;  National Cancer Institute (NCI)
**RECRUITING NOW**
Interventions:  Drug: Cabozantinib S-malate;  Drug: Clostridium butyricum CBM 588 Probiotic Strain;  Biological: Nivolumab
Sponsors:  City of Hope Medical Center;  National Cancer Institute (NCI)
**RECRUITING NOW**
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
